<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953641</url>
  </required_header>
  <id_info>
    <org_study_id>07-134</org_study_id>
    <nct_id>NCT00953641</nct_id>
  </id_info>
  <brief_title>Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy</brief_title>
  <official_title>Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether using Misoprostol vaginally before an
      office endometrial biopsy is performed, will make it easier, more successful and less painful
      to do the procedure.

      The investigators' hypothesis is that vaginal Misoprostol 12 hours prior to endometrial
      biopsy will increase the ease of performing office endometrial biopsy by reducing the need to
      use a tenaculum or a cervical dilator to achieve passage of a biopsy pipelle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial biopsy is a common gynecological office procedure performed to assist in the
      pathological diagnosis of abnormal vaginal bleeding. The procedure can be painful and it may
      be difficult to obtain an endometrial sample with a hard and closed cervix. Giving
      Misoprostol before the procedure may soften the cervix sufficiently to allow an easier and
      more successful test. This medication has been tested before hysteroscopy and in some
      patients it has been shown to be beneficial.

      104 patients need to be recruited for this study. Participants will be divided according to
      pre-menopausal and post-menopausal status. Each of these groups will then be divided into a
      treatment arm (with Misoprostol) and a placebo arm. Participants will place a vaginal
      suppository containing either Misoprostol 400 ug or a placebo 12h or more before their
      appointment for the endometrial biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principle Investigator retired, Resident moved away
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating the ease of an endometrial biopsy by the need to use a tenaculum or a cervical dilator to achieve passage of a biopsy pipelle</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating participants discomfort during the procedure, using a pain scale</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of passage of the pipelle</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects from medications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of the procedure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Menorrhagia</condition>
  <condition>Endometrial Biopsy</condition>
  <condition>Cervical Ripening</condition>
  <arm_group>
    <arm_group_label>Pre-Menopausal 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-Menopausal group, receiving Misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-Menopausal 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will insert a placebo vaginal suppository 12h or more prior to the endometrial biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Menopausal 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-Menopausal patients will insert a Misoprostol vaginal suppository 12h or more prior to the endometrial biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Menopausal 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal suppository prior to the endometrial biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure</description>
    <arm_group_label>Pre-Menopausal 1</arm_group_label>
    <arm_group_label>Post-Menopausal 1</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy</description>
    <arm_group_label>Pre-Menopausal 2</arm_group_label>
    <arm_group_label>Post-Menopausal 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with abnormal uterine bleeding

          -  Age over 35 years

        Exclusion Criteria:

          -  Pregnancy

          -  Allergy to or contraindication to prostaglandin use

          -  Active genital tract infections

          -  Bleeding disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Pierson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Saskatchewan, Dept. of Obstetrics and Gynecology, College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anita Harding, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Dept. of Obstetrics and Gynecology, College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thirza Smith, MD, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Dept. of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilyn Davidson, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Dept. of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Obstetrics and Gynecologic Consultants</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>August 11, 2012</last_update_submitted>
  <last_update_submitted_qc>August 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Anita Harding</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Vaginal Misoprostol</keyword>
  <keyword>Cervical ripening</keyword>
  <keyword>Endometrial biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

